KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $219.0 million.

  • Halozyme Therapeutics' Cash from Operations rose 2272.8% to $219.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $651.6 million, marking a year-over-year increase of 3600.65%. This contributed to the annual value of $651.6 million for FY2025, which is 3600.65% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Cash from Operations of $219.0 million as of Q4 2025, which was up 2272.8% from $178.6 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Cash from Operations ranged from a high of $219.0 million in Q4 2025 and a low of $36.9 million during Q2 2021
  • For the 5-year period, Halozyme Therapeutics' Cash from Operations averaged around $102.9 million, with its median value being $93.3 million (2023).
  • Per our database at Business Quant, Halozyme Therapeutics' Cash from Operations soared by 190096.98% in 2021 and then crashed by 4279.98% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Cash from Operations stood at $82.5 million in 2021, then dropped by 0.08% to $82.5 million in 2022, then increased by 24.14% to $102.4 million in 2023, then surged by 74.36% to $178.5 million in 2024, then increased by 22.73% to $219.0 million in 2025.
  • Its Cash from Operations was $219.0 million in Q4 2025, compared to $178.6 million in Q3 2025 and $99.7 million in Q2 2025.